Moderna says FDA refuses to review its application for experimental flu shot

CNBC Published Updated Stocks
Sign in to save

Why it matters

Moderna's experimental flu shot, mRNA-1010, has been rejected by the FDA for review, contradicting previous feedback from the regulatory agency.

Article tone

Neutral How the article is written, as reported by the source.

Expected market reaction

Bearish Confidence 90% How confidence is read Horizon: Short term Impact: Moderate

Market impact analysis based on bearish sentiment with 90% confidence.

Evidence trail

Evidence
Source CNBC
Claim Moderna says FDA refuses to review its application for experimental flu shot
AI inference Bearish · 90%
Generated 2026-02-10 23:11

AI provenance

Analysed by Llama 3.1 8B Instant (Groq) Methodology v1.0 Generated
Technical identifiers
Provider tag
groq-llama-3.1-8b-instant
Analysis version
groq-llama-3.1-8b-instant
Article id
44203

Original source

Moderna said the move is inconsistent with previous feedback from the FDA on the experimental influenza shot, called mRNA-1010.

Read the full article on CNBC

Original article published by CNBC on February 11, 2026. Analysis and insights provided by AnalystMarkets AI.

Related coverage